Myriad Genetics (MYGN) announces Mark Capone has resigned as President and CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Myriad Announces Leadership Transition
February 6, 2020 4:06 PM ESTR. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO
Mark C. Capone Resigns, Effective Immediately
SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member... More
Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
February 6, 2020 4:05 PM ESTTotal Second-Quarter Revenues of $195.1 MillionSecond-Quarter Diluted EPS of ($0.11) and Adjusted EPS of $0.23
SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced financial results for its fiscal second-quarter 2020, provided an update on recent business highlights and provided revised fiscal year and third-quarter 2020 financial guidance.
"Revenue in the fiscal second quarter fell short of expectations largely due to the prenatal business. Prenatal cash collections were negatively impacted by issues in billing operations that... More
